Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 01 July 2011 | By Katherine R. Leibowitz
On 24 May 2011, the US Food and Drug Administration (FDA) released draft guidance to replace its current guidance on disclosure of financial interests held by clinical investigators.1 The draft guidance reflects the changing landscape both within and outside FDA regarding transparency of financial interests. Consistent with increased public attention to physician-industry financial ties, the tenor of the draft guidance suggests that clinical trial sponsors should expect a more rigorous review by FDA of these financial arrangements. Comments on the draft guidance must be submitted by 25 July 2011.